Noopept

Noopept

Noopept (also called omberacetam, originally GVS-111) is a Russian-developed compound built as a more potent cousin of piracetam. It's a small dipeptide that's roughly 1000 times more potent by weight, and people use it for sharper memory, faster recall, and steadier focus, usually in a 10-30 mg daily window. It also has a mild anxiolytic edge that the classical racetams don't have, which is part of why it tends to feel smoother and less stimulating.
It was originally developed for cognitive decline after stroke and traumatic brain injury, where the human evidence sits. In healthy people the clinical data is essentially absent, so most of what you read online about acute cognitive enhancement is anecdote plus animal research extrapolated forward. That doesn't mean it doesn't work, plenty of people report a real subjective effect on recall and verbal fluency within the first week, but go in knowing the evidence base is thinner than the marketing suggests.

Deep-dive

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) was designed in the mid-1990s at the Zakusov Institute in Moscow by trying to mimic piracetam's structure with a short peptide. The result was a dipeptide that's more potent, has better blood-brain barrier penetration, and adds a few mechanisms piracetam doesn't have. It's prodrug-like: after oral dosing it's rapidly metabolised to cycloprolylglycine, a cyclic dipeptide that's structurally close to an endogenous neuropeptide the brain already produces, and most of the downstream activity is attributed to this metabolite rather than to noopept itself.
The parent compound has a plasma half-life of around 30-60 minutes, and is essentially cleared from the brain within an hour or two. The metabolite persists longer, which is why effects outlast the parent's presence. Oral bioavailability is low, estimated at roughly 10%, which is why sublingual dosing is common, it bypasses first-pass metabolism and reaches the brain faster.
Mechanisms. Several act in parallel.
  • BDNF and NGF upregulation in the hippocampus. This is the most replicated mechanism. A 2008 rat study showed both acute and chronic dosing increased BDNF and NGF mRNA in the hippocampus, and chronic dosing for 28 days didn't produce tolerance, it actually potentiated the neurotrophic effect. BDNF is the protein that strengthens synaptic connections during learning, and chronically low BDNF is linked to depression, age-related cognitive decline, and the early stages of Alzheimer's. Noopept appears to nudge this system upward without burning out
  • AMPA receptor modulation. Like piracetam and aniracetam, noopept acts as a positive allosteric modulator at AMPA receptors, the main fast-excitatory receptor in the brain. It doesn't activate them directly, it makes them more responsive to glutamate. This is the proposed mechanism for the acute memory and learning effects seen in animal models
  • Cholinergic effects. Noopept potentiates cholinergic transmission and protects against memory deficits induced by cholinergic blockade in rats. This is probably why headache and a 'foggy' feeling are common when people don't take a choline source alongside it: the compound increases demand on the acetylcholine system, and if substrate is limited you feel it
  • Anxiolytic action via inhibitory interneurons. A 2010 patch-clamp study showed noopept increases the frequency of inhibitory postsynaptic currents on hippocampal CA1 pyramidal cells by activating local inhibitory interneurons. This is the proposed mechanism for the calming, slightly anxiolytic edge users report, more inhibitory tone in the hippocampus dampens runaway excitatory activity. A later study showed this depends on α7 nicotinic acetylcholine receptors on those interneurons
Human evidence. Thinner than the mechanistic story implies. The most-cited trial is an open-label comparison in patients with mild cognitive disorders from cerebrovascular and post-traumatic causes, where 20 mg/day of noopept for 56 days matched 1200 mg/day of piracetam on cognitive outcomes and showed somewhat better effects on fatigue, anxiety, irritability, and sleep. A separate stroke study in 60 patients found 20 mg/day for 2 months improved MMSE scores and verbal fluency vs no treatment. Both are open-label and Russian, neither is a high-quality placebo-controlled trial. There's no published trial in healthy people, and no trial longer than 56 days. Most of the regulatory and academic interest outside Russia treats it as an investigational compound rather than a proven nootropic
Women. Almost all preclinical work was done in male rodents, and the human trials don't break out results by sex. There's no biological reason to expect the mechanism to differ meaningfully between men and women, the BDNF, AMPA, and cholinergic systems work similarly in both sexes, and oestrogen actually upregulates BDNF independently, which suggests women in higher-oestrogen phases of the cycle may have a slightly higher baseline. Where this matters in practice: women metabolise CNS drugs more slowly on average and experience adverse events more often at standard doses, so starting at 10 mg rather than 20 mg, regardless of bodyweight, is the sensible default. Pregnancy and breastfeeding are an absolute no, there's no safety data
Limitations of the evidence. Almost all the published work comes from one research group in Moscow, which is a reasonable concern about replicability. The two human trials are small, open-label, and in clinical populations. There are no long-term safety studies beyond 56 days, and no trials in healthy adults. The acute cognitive-enhancement claims popular online are extrapolated from rat memory tests, not human RCTs. Worth taking seriously, worth not overstating

Dosage:

  • Standard dose: 10-30 mg/day, taken as 10 mg once or twice daily. The clinical trials used 20 mg/day split as 10 mg twice daily for 56 days, this is the most evidence-based protocol
  • Start low: 10 mg once daily for the first week. Women, smaller-framed people, and anyone sensitive to nootropics should stay at 10 mg until they see how they respond. Higher isn't better, doses above 30 mg/day don't add benefit and increase side effects
  • Sublingual vs oral: Sublingual gives faster onset (15-20 minutes vs 30-45) and probably higher effective levels since oral bioavailability is only around 10%. Take with a small amount of fat (a teaspoon of olive or coconut oil) if dosing orally, it's lipid-soluble and absorbs better
  • Timing: Morning and early afternoon. Avoid evening doses, it can cause insomnia in sensitive users despite the short half-life
  • Cycle: 4-8 weeks on, 2-4 weeks off is the common protocol. Tolerance development is reported anecdotally though one rat study suggests the neurotrophic effect doesn't tolerate. Cycling is mostly precautionary, not strictly necessary based on the data
  • Choline pairing: Add 300-600 mg of Alpha-GPC or CDP-choline if you get a noopept headache. The compound increases acetylcholine demand and dosing a choline source on top resolves this for most people
  • Stacks: Pairs cleanly with caffeine and L-Tyrosine for a focus stack. Pairs with Semax or Selank if you're chasing the BDNF effect from multiple angles. Don't stack with other racetams in the early weeks, you won't know what's doing what

Here's what you can expect:

Most people notice something within the first 3-7 days, not the first dose. The acute, single-dose 'kick' is mild and easy to miss, the build-up effect over a week of consistent dosing is where the subjective benefit shows up. Common reports: easier word recall, smoother verbal fluency, better retention of what you read, slightly lower baseline anxiety, less mental friction switching between tasks. It's not a stimulant. If you're expecting modafinil or caffeine you'll think it's doing nothing.
The effect tends to plateau after 2-4 weeks. Some people find it stops being noticeable around then and benefit from cycling off for a few weeks before returning. Others stay on it long-term without losing the benefit. There's no good way to predict which camp you're in except by trying.
If you feel nothing at 10 mg twice daily after 3 weeks, it's unlikely that doubling the dose will fix that. The responder vs non-responder split is real and probably comes down to baseline BDNF tone and cholinergic function, neither of which you can easily measure.

Side effects & risks:

  • Headache is the most common side effect, especially in the first week. Usually a sign the cholinergic system is being pushed harder than your choline status supports. Adding a choline source resolves it for most people. Persistent headache despite choline means the dose is too high or noopept isn't for you
  • Irritability and restlessness are reported by a minority of users, particularly at higher doses or when dosed late in the day. In the human trial, 3 of 31 patients on noopept reported irritability
  • Insomnia if dosed in the evening, despite the short half-life. The downstream effects on BDNF and the cholinergic system persist longer than the parent compound does
  • Mild blood pressure elevation was reported in 7 of 31 patients in the same trial. The effect is small but worth knowing about if you're already hypertensive or on stimulants
  • Fatigue and brain fog in a subset of users, opposite to the intended effect. Usually resolved by lowering the dose or adjusting choline levels (too much choline can cause it as easily as too little)
  • Mood effects in depression. Some users with major depression report worsening rather than improvement, possibly via the cholinergic effects. If you're depressed, this isn't a good first-line tool
  • No documented serious adverse events in the published trials, but the longest controlled human study is 56 days. Long-term safety beyond a few months is genuinely unknown
  • Drug interactions are theoretically possible with cholinergic drugs (acetylcholinesterase inhibitors), glutamatergic drugs, and anything CNS-active. No major documented interactions but the evidence base is small
  • Pregnancy and breastfeeding: Avoid. No safety data
  • Tolerance and dependence: Mild tolerance is reported with daily use, no withdrawal syndrome documented. Cycling addresses both concerns
🩸

Blood markers

Blood pressure, baseline before starting. A small fraction of users see a modest rise on noopept. If you're already running elevated BP or stacking with stimulants, you want a reference point and should recheck after the first 2 weeks.
Liver enzymes (ALT, AST), baseline if you plan to run it longer than 8 weeks. The compound is hepatically metabolised and long-term safety data thins out past 56 days.
Full lipid panel and fasting glucose, baseline as part of general bloodwork. Animal data suggests noopept may have favourable effects on glucose handling, but nothing useful enough to recommend it for that.
Sold OTC in Russia, regulated as a research chemical or unscheduled supplement in most other countries. Legal status varies, check yours.